WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Wetherspoons adds exciting dishes inspired by global cuisine in a major menu shakeClosing prices for crude oil, gold and other commoditiesMarta says this will be her final year with Brazil's women's national teamHow major US stock indexes fared Thursday, 4/25/2024Wendy Williams' courtMusic Review: St. Vincent's artAllergies can make you miserable. Here's how to track pollen levels near youKylie Minogue plays peekaboo in sparkling black dress as she's honored at the TIME 100 Gala in NYCLady Victoria Hervey dons chic monochrome ensemble as she visits an art exhibition in LondonJapan's Kozuma takes a 1st
3.3134s , 6516.03125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Identities news portal